Analytics of host cell proteins (HCPs): lessons from biopharmaceutical mAb analysis for Gene therapy products. (October 2021)

• Record Type: Journal Article
• Authors: Bracewell, Daniel G; Smith, Victoria; Delahaye, Mike; Smales, C Mark
• Is Part Of: Current opinion in biotechnology. Volume 71(2021)
• Page Start: 98
• Page End: 104
• Publication Date: 2021-10
• Subjects: Biotechnology -- Periodicals; 660.6
• DOI: 10.1016/j.copbio.2021.06.026
• Languages: English
• ISSNs: 0958-1669

Abstract

Graphical abstract: Highlights: Host cell protein analysis in biopharma informs analysis in gene therapy products. Developments in mass spectrometry HCP analysis of gene therapy products. Risk based assessment of HCPs. Abstract : Analytics for host cell protein (HCP) analysis of therapeutic monoclonal antibody preparations have developed enormously. We consider how learnings from this can inform HCP analysis of gene therapy viral vector products. The application of mass spectrometry (MS) approaches for analysis of HCPs in viral vector preparations is being established, although such information remains limited and is yet to be widely applied into process or host cell line development to reduce HCP amounts or risk. As these MS approaches, and the data from them, are applied and become available, the process understanding created will speed process development activity. We describe technologies that have been, or can be, applied to viral vector HCP analysis to aid process development, reduce HCP amounts, identify critical HCPs and thus inform risk assessment and management based on a knowledge of specific HCPs, ultimately delivering safe and efficacious gene therapy products to the clinic.